A federal jury in the United States has found that Pfizer violated anti-racketeering laws in promoting its epilepsy drug Neurontin for unapproved uses and must pay at least US$142 million ($201 million) in damages.
The jury sided with California-based Kaiser Foundation Health Plan and Kaiser Foundation Hospitals, the first to try a Neurontin case against the drugmaker.
Kaiser claimed it was misled into believing Neurontin was effective for off-label treatment of migraines, bipolar disorder and other conditions.
Pfizer argued that Kaiser physicians still recommend the drug for those uses.
AdvertisementAdvertise with NZME.
Latest from World
French police fatally shoot a man suspected of setting fire to a synagogue
Police in Rouen stop synagogue arson attempt, suspect killed.